Ashwagandha and antidepressants have been taken together in small clinical trials. There are also reports of suspected adverse interactions. Neither set of findings gives a universal answer: a short trial cannot clear every combination, and a case report cannot tell you how often a reaction happens. If you take an antidepressant, have your prescriber or pharmacist review the combination before adding ashwagandha.

This article is educational and is not medical advice. Don't start, stop or change an antidepressant or any supplement based on a web article. Talk to your prescriber or pharmacist before combining ashwagandha with an antidepressant. If you are thinking about suicide or are in crisis, call or text 988 in Canada or the U.S., any time. If your safety is at risk right now, call 911.

What the SSRI add-on trials found

In a six-week trial, 40 adults with generalized anxiety disorder who were already taking SSRIs received ashwagandha root extract or a placebo. Anxiety scores fell more with the extract, and the published abstract reported no adverse effects (Fuladi 2021). This was a small study in a diagnosed patient group, rather than a test of everyday stress or of every antidepressant.

A separate six-week trial enrolled 30 people with obsessive-compulsive disorder, all taking SSRIs. Symptom scores improved more in the ashwagandha group, and the abstract reported no adverse events (Jahanbakhsh 2016). The treatment group's starting symptom scores were higher, which complicates a simple comparison of how far scores fell.

These findings are preliminary signals about adding a particular extract to supervised treatment. They do not establish ashwagandha as a replacement for medication, a treatment for depression, or a safe addition to any SSRI. Neither trial was large or long enough to rule out uncommon or delayed harm. We describe the trials without turning their research doses into a self-treatment plan.

The adverse-reaction reports matter too

A Polish retrospective review identified seven reports involving ashwagandha and antidepressants among 30 selected adaptogen/antidepressant adverse-event reports. One involved severe diarrhea requiring hospitalization with sertraline. Others involved escitalopram, paroxetine or reboxetine, with symptoms including muscle pain and gastrointestinal problems (Siwek 2023).

These were selected reports of suspected reactions, not a study following all users. The seven cases are not a reaction rate. Patients were also taking other medicines, so the reports cannot cleanly isolate ashwagandha's contribution. The authors proposed overlapping side effects and altered drug handling as possible explanations; they did not establish a predictable change in antidepressant blood levels.

A separate case report described recurrent narrowing of brain blood vessels with intracranial bleeding in a person with a history of ashwagandha, medical marijuana and SNRI use (Patel 2023). The multiple exposures make it impossible to attribute that case to ashwagandha alone or establish a specific ashwagandha/SNRI interaction.

Can ashwagandha and an SSRI cause serotonin syndrome?

A 2025 Neurology conference abstract reported serotonin syndrome in a person taking ashwagandha and escitalopram (Hanly-Jorda 2025). It is a single case reported in a conference supplement, with less detail available than a full clinical paper. It raises a safety concern without proving the combination caused the event or establishing how often it might happen. Saying there are no reports would overlook it.

Serotonin syndrome can be life-threatening. MedlinePlus lists its symptoms as including agitation or restlessness, hallucinations, a fast heartbeat with high blood pressure, a raised body temperature, overactive reflexes, loss of coordination, diarrhea, and nausea or vomiting, and says to contact your provider right away if they appear (MedlinePlus). If symptoms are severe or worsening quickly, get emergency care. Do not try to manage a suspected reaction by rearranging supplement timing.

Get The Signal by email. New research, grade changes and safety notes, about every two weeks. Subscribe free

Liver, thyroid, and drowsiness cautions still apply

Ashwagandha has risks apart from a possible antidepressant interaction. Australia's TGA has warned of a very rare risk of liver injury, in a 2024 safety advisory and again in a July 2026 safety update, and advises people with current or past liver problems to avoid products containing it (TGA 2024; TGA 2026). Stop taking it and seek medical care if you notice yellowing of the skin or eyes, dark urine, or persistent abdominal pain.

NCCIH lists drowsiness and stomach symptoms among possible effects, cautions about interactions with sedatives and thyroid medicines, and advises against use during pregnancy or breastfeeding. It also does not recommend ashwagandha for people with thyroid or autoimmune disorders (NCCIH). A pharmacist should review your whole medication list, including sleep medicines, rather than just the antidepressant.

Does taking them at different times make it safe?

The evidence above does not establish a protective spacing interval. The trials and reports do not show that separating the doses by a few hours prevents suspected interactions or ashwagandha's liver and thyroid effects. Ask about the exact product and medicine instead of assuming that morning versus evening solves the question.

What to take to your prescriber or pharmacist

  • The antidepressant name, dose, how long you have taken it, and any recent changes.
  • A photo of the full supplement label, including the plant parts, extract details and other ingredients.
  • Every other medicine and supplement you use, including sleep products and nonprescription medicines.
  • Any liver or thyroid history, and the symptom you hope the supplement will address. Ask whether a medication review would be more useful.
Our interaction checker covers selected supplement combinations. It does not check prescription medicines or clear this combination. See the checker and its limits
The ashwagandha profile carries our current evidence grade, safety cautions and ingredient-specific research-alert signup. Read the ashwagandha profile

How to think about it

The evidence includes small positive SSRI add-on trials and suspected adverse reactions, including a conference report of serotonin syndrome. That supports checking the exact combination with a clinician, not giving it blanket clearance. Keep prescribed treatment decisions with your prescriber, and do not treat an extract sold for stress as an interchangeable substitute.

References

  • Fuladi S, Emami SA, Mohammadpour AH, et al. "Assessment of the Efficacy of Withania somnifera Root Extract in Patients with Generalized Anxiety Disorder: A Randomized Double-blind Placebo-Controlled Trial." Current Reviews in Clinical and Experimental Pharmacology, 2021;16(2):191–196. PMID: 32282308.
  • Jahanbakhsh SP, Manteghi AA, Emami SA, et al. "Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial." Complementary Therapies in Medicine, 2016;27:25–29. PMID: 27515872.
  • Siwek M, Woroń J, Wrzosek A, Gupało J, Chrobak AA. "Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs." Frontiers in Pharmacology, 2023;14:1271776. PMID: 37829299.
  • Patel PA, Sanborn E, Then R, Williams DM. "Recurrent Reversible Cerebral Vasoconstriction Syndrome: A Report of Two Cases." Cureus, 2023;15(8):e42992. PMID: 37671233.
  • Hanly-Jorda FM, Bilik SM, Patel N, Bilik AJ. "Serotonin Syndrome Induced by the Pharmacological Interaction of Withania Somnifera and Escitalopram: A Case Report (P12-2.009)." Neurology, 2025;104(7 Supplement 1). Conference abstract. doi:10.1212/WNL.0000000000210450.
  • National Center for Complementary and Integrative Health (NCCIH). "Ashwagandha: Usefulness and Safety." Accessed October 24, 2026. https://www.nccih.nih.gov/health/ashwagandha
  • Therapeutic Goods Administration (TGA). "Medicines containing Withania somnifera (Withania, Ashwagandha)." Consumer safety advisory, February 22, 2024. https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/medicines-containing-withania-somnifera-withania-ashwagandha
  • Therapeutic Goods Administration (TGA). "Withania somnifera (Ashwagandha) and very rare risk of liver injury." Medicine Safety Update, July 7, 2026. https://www.tga.gov.au/news/safety-updates/withania-somnifera-ashwagandha-and-very-rare-risk-liver-injury
  • MedlinePlus, U.S. National Library of Medicine. "Serotonin syndrome." Accessed October 24, 2026. https://medlineplus.gov/ency/article/007272.htm

Evidence search: PubMed, October 24, 2026, for ashwagandha or Withania somnifera with antidepressants, SSRIs, named SSRIs or serotonin syndrome, supplemented by regulator guidance and the Neurology conference record. Some trial details above are available to us only in published abstracts. This is a targeted evidence summary, not a systematic review.